BioSpace News Archive

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced that the first subject has been dosed in a Phase I trial evaluating CBP-174 in healthy adult subjects.

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate.

Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Tuesday, June 1 at 9:00 a.m. ET.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,013,785.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1st to 4th.

Novan, Inc., announced that it has filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company to implement a one-for-ten reverse split of its issued and outstanding common stock.

Alloy Therapeutics and Pyxis Oncology announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases.

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer of Chimerix, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the appointment of Sara Zaknoen, M.D., to the company’s Board of Directors.